Global Hydronephrosis Therapies Market 2019-2023

SKU ID : TNV- 12593791

Publishing Date : 02-Nov-2018

No. of pages : 116

PRICE
2500
4000


  • About Hydronephrosis
    Hydronephrosis is a condition when the inside of the kidney gets dilated or stretched and usually analgesics and drugs for kidney stones are used as therapeutics for hydronephrosis.
    Analysts forecast the Global Hydronephrosis Therapies Market to grow at a CAGR of 9.14% during the period 2019-2023.

    Covered in this report
    The report covers the present scenario and the growth prospects of the hydronephrosis therapies market. To calculate the market size, the report considers the revenue generated by the sale of drugs for the treatment of hydronephrosis across the globe.

    The market is divided into the following segments based on geography:
    • Americas
    • APAC
    • EMEA

    Report, hydronephrosis therapies market 2019-2023, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

    Key vendor
    • Allergan
    • F. Hoffmann-La Roche
    • Novartis
    • Pfizer
    • Teva Pharmaceutical Industries
    Market driver
    • growing prevalence of kidney diseases that result in a higher incidence of hydronephrosis
    • For a full, detailed list, view our report

    Market challenge
    • Availability of alternate therapies
    • For a full, detailed list, view our report

    Market trend
    • Increasing awareness of kidney diseases
    • For a full, detailed list, view our report

    Key questions answered in this report
    • What will the market size be in 2023 and what will the growth rate be?
    • What are the key market trends?
    • What is driving this market?
    • What are the challenges to market growth?
    • Who are the key vendors in this market space?
    • What are the market opportunities and threats faced by the key vendors?
    • What are the strengths and weaknesses of the key vendors?

    You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

    Detailed TOC of Global Hydronephrosis Therapies Market 2019-2023

    PART 01: EXECUTIVE SUMMARY
    PART 02: SCOPE OF THE REPORT
    PART 03: MARKET LANDSCAPE
    • Market ecosystem
    • Market characteristics
    • Market segmentation analysis
    PART 04: MARKET SIZING
    • Market definition
    • Market sizing 2018
    • Market size and forecast 2018-2023
    PART 05: FIVE FORCES ANALYSIS
    • Bargaining power of buyers
    • Bargaining power of suppliers
    • Threat of new entrants
    • Threat of substitutes
    • Threat of rivalry
    • Market condition
    PART 06: MARKET SEGMENTATION BY PRODUCT
    • Market segmentation by product
    • Comparison by product
    • Antibiotic therapy - Market size and forecast 2018-2023
    • Other therapies - Market size and forecast 2018-2023
    • Market opportunity by product
    PART 07: CUSTOMER LANDSCAPE
    PART 08: GEOGRAPHIC LANDSCAPE
    • Geographic segmentation
    • Geographic comparison
    • Americas - Market size and forecast 2018-2023
    • EMEA - Market size and forecast 2018-2023
    • APAC - Market size and forecast 2018-2023
    • Key leading countries
    • Market opportunity
    PART 09: DECISION FRAMEWORK
    PART 10: DRIVERS AND CHALLENGES
    • Market drivers
    • Market challenges
    PART 11: MARKET TRENDS
    PART 12: VENDOR LANDSCAPE
    • Overview
    • Landscape disruption
    • Competitive scenario
    PART 13: VENDOR ANALYSIS
    • Vendors covered
    • Vendor classification
    • Market positioning of vendors
    • Allergan
    • F. Hoffmann-La Roche
    • Novartis
    • Pfizer
    • Teva Pharmaceutical Industries
    PART 14: APPENDIX
    • Research methodology
    • List of abbreviations
    PART 15: EXPLORE TECHNAVIO


    Exhibit 01: Global urological disorder drugs market
    Exhibit 02: Segments of global urological disorder drugs market
    Exhibit 03: Market characteristics
    Exhibit 04: Market segments
    Exhibit 05: Market definition - Inclusions and exclusions checklist
    Exhibit 06: Market size 2018
    Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
    Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
    Exhibit 09: Five forces analysis 2018
    Exhibit 10: Five forces analysis 2023
    Exhibit 11: Bargaining power of buyers
    Exhibit 12: Bargaining power of suppliers
    Exhibit 13: Threat of new entrants
    Exhibit 14: Threat of substitutes
    Exhibit 15: Threat of rivalry
    Exhibit 16: Market condition - Five forces 2018
    Exhibit 17: Product - Market share 2018-2023 (%)
    Exhibit 18: Comparison by product
    Exhibit 19: Antibiotic therapy - Market size and forecast 2018-2023 ($ millions)
    Exhibit 20: Antibiotic therapy - Year-over-year growth 2019-2023 (%)
    Exhibit 21: Other therapies - Market size and forecast 2018-2023 ($ millions)
    Exhibit 22: Other therapies - Year-over-year growth 2019-2023 (%)
    Exhibit 23: Market opportunity by product
    Exhibit 24: Customer landscape
    Exhibit 25: Market share by geography 2018-2023 (%)
    Exhibit 26: Geographic comparison
    Exhibit 27: Americas - Market size and forecast 2018-2023 ($ millions)
    Exhibit 28: Americas - Year-over-year growth 2019-2023 (%)
    Exhibit 29: Top 3 countries in Americas
    Exhibit 30: EMEA - Market size and forecast 2018-2023 ($ millions)
    Exhibit 31: EMEA - Year-over-year growth 2019-2023 (%)
    Exhibit 32: Top 3 countries in EMEA
    Exhibit 33: APAC - Market size and forecast 2018-2023 ($ millions)
    Exhibit 34: APAC - Year-over-year growth 2019-2023 (%)
    Exhibit 35: Top 3 countries in APAC
    Exhibit 36: Key leading countries
    Exhibit 37: Market opportunity
    Exhibit 40: Impact of drivers and challenges
    Exhibit 41: Vendor landscape
    Exhibit 42: Landscape disruption
    Exhibit 43: Vendors covered
    Exhibit 44: Vendor classification
    Exhibit 45: Market positioning of vendors
    Exhibit 46: ALLERGAN - Vendor overview
    Exhibit 47: ALLERGAN - Business segments
    Exhibit 48: ALLERGAN - Organizational developments
    Exhibit 49: ALLERGAN - Geographic focus
    Exhibit 50: ALLERGAN - Segment focus
    Exhibit 51: ALLERGAN - Key offerings
    Exhibit 52: ALLERGAN: Key customers
    Exhibit 53: F. Hoffmann-La Roche - Vendor overview
    Exhibit 54: F. Hoffmann-La Roche - Business segments
    Exhibit 55: F. Hoffmann-La Roche - Organizational developments
    Exhibit 56:
    Exhibit 57: F. Hoffmann-La Roche - Geographic focus
    Exhibit 58: F. Hoffmann-La Roche - Segment focus
    Exhibit 59: F. Hoffmann-La Roche - Key offerings
    F. Hoffmann-La Roche: Key customers
    Exhibit 60: Novartis - Vendor overview
    Exhibit 61: Novartis - Business segments
    Exhibit 62: Novartis - Organizational developments
    Exhibit 63: Novartis - Geographic focus
    Exhibit 64: Novartis - Segment focus
    Exhibit 65: Novartis - Key offerings
    Exhibit 66: Novartis - Key customers
    Exhibit 67: Pfizer - Vendor overview
    Exhibit 68: Pfizer - Organizational developments
    Exhibit 69: Pfizer - Geographic focus
    Exhibit 70: Pfizer - Segment focus
    Exhibit 71: Pfizer - Key offerings
    Exhibit 72: Pfizer - Key customers
    Exhibit 73: Teva Pharmaceutical Industries - Vendor overview
    Exhibit 74: Teva Pharmaceutical Industries - Business segments
    Exhibit 75: Teva Pharmaceutical Industries - Organizational developments
    Exhibit 76: Teva Pharmaceutical Industries - Geographic focus
    Exhibit 77: Teva Pharmaceutical Industries - Segment focus
    Exhibit 78: Teva Pharmaceutical Industries - Key offerings
    Exhibit 79: Teva Pharmaceutical Industries: Key customers

    Keyplayers in Global Hydronephrosis Therapies Market 2019-2023

    Allergan
    F. Hoffmann-La Roche
    Novartis
    Pfizer
    Teva Pharmaceutical Industries